Is Merck (NYSE:MRK) Gaining Fresh Momentum After Latest Target Boost?
Is Merck (NYSE:MRK) Gaining Fresh Momentum After Latest Target Boost? Kalkine Media
Covered in this story
Analyst targets on Merck & Co.
- Morgan Stanley: $143 → $177 by Oct 2027 · Overweight via MarketBeat
- JPMorgan: $140 → $165 by Oct 2027 · Overweight via MarketBeat
- Scotiabank: $149 → $180 by Sep 2027 · sector outperform via marketbeat.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $MRK yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Merck & Co. →Dalsna Finance is currently tracking 33 stories mentioning Merck & Co., the earliest published 10 Jul 2026.
Summary aggregated from Kalkine Media's public RSS feed. The full reporting belongs to Kalkine Media — please read it on their site.